Cetuximab in the treatment of metastatic colorectal cancer

Expert Opinion on Biological Therapy

Volumn 7, Issue 2, 2007, Pages 243-256

  Moosmann, Nicolas ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; EGFR; Irinotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; PANITUMUMAB; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANGIOGENESIS; ASTHENIA; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; HAIR DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PARONYCHIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEBORRHEIC DERMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846678420     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.2.243     Document Type: Review

References (67)

1. TOURNIGAND C, ANDRE T, ACHILLE E et al.: FOLFIRI followed by FOLFOX or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. (2004) 22:229-237.
2. GOLDBERG RM, SARGENT DJ, MORTON RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. (2004) 22:23-30.
3. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J. Clin. Oncol. (2005) 23(16S):1s, Abstract 2.
4. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342. • Phase III trial that led to approval of bevacizumab in the first-line treatment of metastatic CRC.
5. ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. (2001) 19(Suppl. 18):32S-40S.
6. KRAUSE DS, VAN ETTEN RA: Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. (2005) 353:172-187.
7. MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21:2787-2799.
8. MIETTINEN PJ, BERGER JE, MENESES J et al.: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature (1995) 376:337-341.
9. THREADGILL DW, DLUGOSZ AA, HANSEN LA et al.: Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 269(5221):230-234.
10. NICHOLSON RI, GEE JM, HARPER ME et al.: EGFR and cancer prognosis. Eur. J. Cancer (2001) 37(Suppl. 4):S9-S15.
11. GOLDSTEIN NI, PREWETT M, ZUKLYS K et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
12. FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3(5):391-400.
13. HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005). 23(5):1011-27.
14. VINCENZI B, SANTINI D, RUSSO A et al.: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann. Oncol. (2006) 17:835-841. • Explains the close interactions between cetuximab and VEGF.
15. VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. (2005) 23:3536-3544.
16. DELBALDO C, PIERGA JY, DIERAS V et al.: Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer (2005) 41(12):1739-1745.
17. TABERNERO J, CERVANTES A, MARTINELLI E et al.: Optimal dose of cetuximab given every 2 weeks (q2w): a Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J. Clin. Oncol. (2006) 24(18S):142s, Abstract 3085.
18. PREWETT MC, HOOPER AT, BASSI R et al.: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. (2002) 8:994-1003.
19. LIANG K, ANG KK, MILAS L et al.: The epidermal growth factor receptor mediates radioresistance. Int. J. Radiat. Oncol. Biol. Phys. (2003) 57:246-254.
20. BONNER JA, RAISCH KP, TRUMMELL HQ et al.: Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. (2000) 18(21 Suppl.):47S-53S.
21. HUANG SM, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
22. BONNER JA, BUCHSBAUM DJ, RUSSO SM et al.: Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(2 Suppl.):2-10.
23. ROSENBERG AH, LOEHRER PJ, NEEDLE MN et al.: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2002) 21:134a, Abstract 536.
24. FOLPRECHT G, LUTZ MP, SCHOFFSKI P et al.: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. (2006) 17(3):450-456.
25. PEETERS M, RAOUL JL, VAN LAETHEM JL et al.: Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). ECCO Annual Meeting (2005) Abstract 664.
26. VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) +/-cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J. Clin. Oncol. (2006) 24(18S):148s, Abstract 3509.
27. HEINEMANN V, FISCHER VON WEIKERSTHAL L et al.: Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first-line therapy for patients with metastatic colorectal cancer (CRC): preliminary results of a randomised Phase II trial of the AIO CRC Study Group. J. Clin. Oncol. (2006) 24(18S):158s, Abstract 3550.
28. DIAZ-RUBIO E, TABERNERO J, VAN CUTSEM E et al.: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): an international Phase II study. J. Clin. Oncol. (2005) 23(16S):254s, Abstract 3535.
29. DITTRICH C, HOEHLER T, LORDICK F et al.: A Phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC). Preliminary results. World Congress on Gastrointestinal Cancer (WCGI) (2006) Abstract O-019.
30. COLUCCI G, GIULIANI F, MATTIOLI R et al.: FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J. Clin. Oncol. (2006) 24(18S):160s, Abstract 3559.
31. DAKHIL S, COSGRIFF T, HEADLEY D et al.: Cetuximab plus FOLFOX6 as first line therapy for metastatic colorectal cancer (An International Oncology Network study, I-03-002). J. Clin. Oncol. (2006) 24(18S):160s, Abstract 3557.
32. BORNER M, MINGRONE W, KOEBERLE D et al.: The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. (2006) 24(18S):158s, Abstract 3551.
33. LANG I, ZALUSKI J, CHANGCHEIN CR et al.: Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). Preliminary safety results (CRYSTAL). J. Clin. Oncol. (2006) 24(18S):159s, Abstract 3555.
34. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345. •• The BOND-1 study led to approval of cetuximab in combination with irinotecan after progression on prior irinotecan-based therapy.
35. SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001) 20:2a, Abstract 7.
36. SALTZ LB, MEROPOL NJ, LOEHRER PJ et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1208.
37. WILKE H, GLYNNE-JONES R, THALER J et al.: MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. J. Clin. Oncol. (2006) 24(18S):158s, Abstract 3549.
38. SOUGLAKOS J, KALYKAKI A, VAMVAKAS L et al.: Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann. Oncol. (2006) (In Press).
39. LENZ HJ, MAYER RJ, MIRTSCHING B et al.: Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(16S):255s: Abstract 3536.
40. ABUBAKR Y, ENG C, WONG L et al.: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 800 patients in a randomized Phase III trial (EPIC). J. Clin. Oncol. (2006) 24(18S):160s, Abstract 3556.
41. SALTZ L, LENZ HJ, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinocecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J. Clin. Oncol. (2005) 23(16S):248s, Abstract 3508.
42. SAUER R, BECKER H, HOHENBERGER W et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. (2004) 351:1731-1740.
43. RODEL C, GRABENBAUER GG, PAPADOPOULOS T et al.: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J. Clin. Oncol. (2003) 21:3098-3104.
44. RYAN DP, NIEDZWIECKI D, HOLLIS D et al.: Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J. Clin. Oncol. (2006) 24:2557-2562.
45. BONNER JA., HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354(6):567-578. • Phase III trial investigating the efficacy of cetuximab plus radiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
46. MACHIELS JP, SEMPOUX C, SCALLIET P et al.: Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. J. Clin. Oncol. (2006) 24(18S):159s, Abstract 3552.
47. CHUNG KY, MINSKY B, SCHRAG D et al.: A pilot trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with locally-advanced rectal cancer. J. Clin. Oncol. (2006) 24(18S):161s, Abstract 3560.
48. ARNOLD D, HIPP M, REESE T et al.: Phase I/II study of cetuximab, capecitabine, and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). J. Clin. Oncol. (2006) 24(18S):164s, Abstract 3574.
49. PEREZ-SOLER R, SALTZ L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. (2005) 23:5235-5246.
50. SEGAERT S, TABERNERO J, CHOSIDOW O et al.: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch Dermatol. Ges. (2005) 3:599-606.
51. SEGAERT S, VAN CUTSEM E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. (2005) 16:1425-1433.
52. ROBERT C, SORIA JC, SPATZ A et al.: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. (2005) 6:491-500.
53. PEREZ-SOLER R, DELORD JP, HALPERN A et al.: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 10:345-356.
54. DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041-1047.
55. SALTZ LB, COX JV, BLANKE C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. (2000) 343:905-914.
56. KOHNE CH, VAN CUTSEM E, WILS J et al.: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J. Clin. Oncol. (2005) 23:4856-4865.
57. SCHRAG D, CHUNG KY, FLOMBAUM C, SALTZ L: Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. (2005) 97(16):1221-1224.
58. CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23:1803-1810.
59. LENZ, HJ, MAYER RJ, GOLD PJ et al.: Activity of cetuximab in patients with metastatic colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. (2004) 23:248, Abstract 3510.
60. FRANCOUAL M, ETIENNE-GRIMALDI MC, FORMENTO JL et al.: EGFR in colorectal cancer: more than a simple receptor. Ann. Oncol. (2006) 17:962-967.
61. LIEVRE A, BACHET JB, LE CORRE D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006). 66(8):3992-3995.
62. MORONI M, VERONESE S, BENVENUTI S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. (2005) 6(5):279-286.
63. SALTZ L, KIES MS, ABBRUZZESE JL et al.: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 22:204, Abstract 817.
64. TEJPAR S, PEETERS M, HUMBLET Y et al.: Dose-escalating study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. J. Clin. Oncol. (2006) 24(18S):159s, Abstract 3554.
65. FOLPRECHT G, GROTHEY A, ALBERTS S et al.: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. (2005) 16(8):1311-1319.
66. ADAM R: Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol. (2003) 14(Suppl. 2):ii13-ii16.
67. http://ctep.cancer.gov/forms/CTCAEv3.pdf Cancer Therapy Evaluation Program (National Cancer Institute), Common Terminology Criteria for Adverse Events (version 3.0).